Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 0.84 |
| ▸ | GABRD | O14764 | 1/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | KLK3 | P07288 | 1/20 | 0.84 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.84 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.84 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.84 |
| ▸ | CNR1 | P21554 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.84 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.84 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.84 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.84 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.84 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.84 |
| ▸ | GABRE | P78334 | 1/20 | 0.84 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16166900 | 0.92 | AR (0.85) | ARGABRPGABRDNR1I2NR3C1 | |
| Enzalutamide SCHEMBL189749 | 0.91 | AR (1.00) | ARGABRPGABRDNR1I2NR3C1 | |
| Enzalutamide SCHEMBL29352764 | 0.91 | AR (1.00) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL18269749 | 0.91 | AR (0.84) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL20664212 | 0.91 | AR (0.83) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL24831438 | 0.90 | AR (0.82) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL189439 | 0.90 | AR (0.81) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL10020938 | 0.90 | AR (0.81) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL29140517 | 0.90 | AR (0.81) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL565106 | 0.89 | ABCG2 (0.83) | ARGABRPGABRDNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023275091-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Química Sintética, S.A. (ES) | 2023-01-05 | — | — | WO | disclosed |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-20210000812-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200299243-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-09-24 | — | — | US | disclosed |
| US-10626091-B2 | Process for the preparation of enzalutamide | LAURUS LABS LIMITED (IN) | 2020-04-21 | — | — | US | disclosed |
| US-10544110-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190262315-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190240199-A1 | TREATMENT FOR GLIOBLASTOMA | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2019-05-02 | — | — | US | disclosed |
| US-9023879-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | AR 8/4885GABRP 2719/4885GABRD 3144/4885 |
| US-20200299243-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | AR 1/4885GABRP 1342/4885GABRD 112/4885 |
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | AR 266/4885GABRP 4093/4885GABRD 3287/4885 |
| US-20210000812-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-10626091-B2 | Process for the preparation of enzalutamide | KLK4, KLK5, KLK1 | AR 8/4885GABRP 2719/4885GABRD 3144/4885 |
| US-20190240199-A1 | TREATMENT FOR GLIOBLASTOMA | EGFR, ERBB3, AR | AR 3/4885GABRP 849/4885GABRD 1601/4885 |
| US-20190262315-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885GABRP 3568/4885GABRD 3622/4885 |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | AR 266/4885GABRP 4093/4885GABRD 3287/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885GABRP 2459/4885GABRD 3707/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885GABRP 3568/4885GABRD 3622/4885 |
| US-10544110-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | AR 1/4885GABRP 2012/4885GABRD 1653/4885 |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885GABRP 1342/4885GABRD 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.